XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO^® has now received approval as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) marking the second approved indication of XPOVIO^® in China.
- Results from the registrational SEARCH study in China showed that the overall response rate (ORR) among the 60 Chinese patients treated with XPOVIO^® met the study's prespecified primary endpoint.
- XPOVIO^® is an oral drug with a novel mechanism of action. Antengene is currently developing multiple combination regimens of XPOVIO^® for the treatment of various indications including myelofibrosis (MF), T-cell non-Hodgkin's lymphoma (T-NHL), and endometrial cancer.
- XPOVIO^® has been approved for health insurance coverage in the mainland of China, Australia, Singapore and South Korea. Furthermore, Antengene has submitted new drug applications (NDAs) for XPOVIO^® in other ASEAN markets including Thailand, Malaysia and Indonesia. Approvals in these markets are anticipated in the second half of 2024.